Shortterm Management Goals

In the short term, our goal with MMM is to diminish the immediate possible morbidities at presentation, with the least amount of expense and toxicity from therapy. Therefore, the patient who presents with asymptomatic or minimally symptomatic disease may most appropriately be observed (see Figure 49.1). To date, no survival benefit has been demonstrated for reduction of asymptomatic splenomegaly, reduction of asymptomatic leukocytosis, or improvements in mild anemia (i.e., hemoglobin >11 g/dL).

0 0

Post a comment